Latest 10-Q quarterly reports
NASDAQ
Constellation Energy Corporation announced robust financial and operational performance for the first quarter of 2026, driven by the successful integration of Calpine and favorable market conditions.
NASDAQ
MRBK
Meridian CORPMeridian Corporation reported a decrease in net income for Q1 2026 compared to the prior year, primarily driven by a significant increase in the provision for credit losses and higher operating expenses.
NYSE
ESCO Technologies Inc. reported significant year-over-year growth in net sales and earnings for the second quarter of fiscal year 2026, driven by strong performance across its segments, and announced a transformative acquisition of Megger Group Limited.
NYSE
Tejon Ranch Co. announced its first quarter 2026 financial results, showing a net income attributable to common stockholders of $0.15 million, a significant improvement from a net loss of $1.46 million in the prior year period.
NASDAQ
C&F Financial Corporation reported a significant increase in net income for the first quarter of 2026, driven by robust performance in its community banking and mortgage banking segments, despite a net loss in its consumer finance operations.
Accendra Health's Q1 2026 results show a revenue decline driven by a major contract termination, alongside progress in its balance sheet optimization transaction.
NASDAQ
Esquire Financial Holdings reported a 7.0% increase in net income for the first quarter of 2026, driven by strong growth in its loan portfolio, particularly in its specialized litigation lending sector.
NASDAQ
BV Financial reported a decrease in net income for Q1 2026 compared to the prior year, primarily driven by increased compensation expenses, including a significant executive payout.
OQB
Circle Energy, Inc. filed its Q1 2026 10-Q, detailing operational status, financial condition, and future plans, with no revenue generated yet.
NYSE
SYK
Stryker CORPStryker Corporation announced its first quarter 2026 financial results, with net sales increasing by 2.6% to $6.02 billion, driven by higher unit volumes across key segments.
NASDAQ
INTG
Intergroup CORPThe InterGroup Corporation reported a net income of $595,000 for the third quarter of fiscal year 2026, a significant improvement from the prior year's net loss, driven by strong performance in hotel operations and a gain on real estate sale.
OTC.Pink
Portsmouth Square, Inc. reported improved hotel operations for the third quarter of fiscal year 2026, with net income of $571,000 compared to a net loss of $712,000 in the prior year period.
Universal Token, Inc. filed its Q1 2026 Form 10-Q, reporting a net loss of $17,725 and highlighting substantial doubt about its ability to continue as a going concern.
Beacon Financial Corporation announced a significant increase in net income for the first quarter of 2026, driven by higher net interest income and non-interest income.
OID
Hills Bancorporation announced a significant increase in net income for the first quarter of 2026, driven by higher net interest income and a decrease in credit loss expenses.
NOTR
Nowtransit INCBioScience Health Innovations Inc. reported a net loss for the first quarter of 2026, with revenues declining year-over-year, attributed to sales channel adjustments and a rescheduled major order, while advancing its patent-pending product pipeline.
NASDAQ
CF Bankshares Inc. reported a 13.5% increase in net income for the first quarter of 2026, driven by higher net interest income and noninterest income, despite a rise in noninterest expense.
NASDAQ
International Money Express reports a significant decrease in net income for Q1 2026, largely due to a contraction in the retail remittance market and ongoing merger preparations with Western Union.
NASDAQ
FOXA
Fox CORPFox Corporation reported a decrease in revenues and net income for the third quarter and first nine months of fiscal year 2026, primarily driven by lower advertising revenue and increased operating expenses.
IMG
Cimg INCCIMG Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing significant revenue growth driven by new product series, but also highlighting substantial net losses and ongoing concerns about its ability to continue as a going concern.
NASDAQ
XGN
Exagen INCExagen Inc. reported an 11.7% increase in revenue for the first quarter of 2026, driven by biomarker enhancements and a growing average selling price.
NYSE
Circle Internet Group reports a 20% increase in total revenue to $694 million for Q1 2026, driven by reserve income and other revenue growth, while net income from continuing operations decreased by 15% to $55 million.
NASDAQ
Forte Biosciences reported a net loss of $22.1 million for Q1 2026, with research and development expenses significantly increasing, while cash reserves remain substantial following a recent public offering.
AMEX
MAIA Biotechnology, Inc. reported its first quarter 2026 financial results, highlighting increased operating expenses and significant cash inflow from financing activities, while advancing its lead oncology drug candidate, ateganosine.
NASDAQ
MoonLake Immunotherapeutics reports increased R&D spending and net loss in Q1 2026, driven by clinical trial progression and stock option expense, while maintaining sufficient capital through 2027.
NASDAQ
American Battery Technology Company reported a significant increase in revenue for the third quarter of fiscal year 2026, driven by higher production volumes and market prices, while also addressing material weaknesses in internal controls.
NASDAQ
Envoy Medical, Inc. filed its Q1 2026 Form 10-Q, detailing financial performance, progress on its Acclaim CI product, and ongoing operational challenges.
NYSE
Global Business Travel Group, Inc. reported a 35% increase in revenue for Q1 2026, reaching $840 million, but net income decreased to $54 million from $75 million in the prior year.
NASDAQ
Priority Technology Holdings reported an 11.1% increase in revenue for the first quarter of 2026, reaching $249.6 million, driven by growth across its Merchant Solutions, Payables, and Treasury Solutions segments.
NASDAQ
Heron Therapeutics reported a net loss of $8.1 million for Q1 2026, with net product sales decreasing to $34.7 million compared to $38.9 million in the prior year period.